Potential Drug Target Or Biomarker for SLC25A35 (G399512)

Target Name: SLC25A35

NCBI ID: G399512

SLC25A35

Potential Drug Target Or Biomarker for SLC25A35

SLC25A35 is a member of the Absolute Carrier Family 25, which is a family of transmembrane proteins that play a crucial role in the transport of various molecules across cell membranes. SLC25A35 is a protein that is expressed in various tissues and cells throughout the body, and it has been identified as a potential drug target or biomarker.

The Absolute Carrier Family 25 consists of several related proteins that share a conserved transmembrane domain and a unique catalytic mechanism for transporting various molecules across cell membranes. These proteins are characterized by their ability to transport a wide variety of molecules, including ions, proteins, and small molecules. They do this by using different transmembrane domains, which are responsible for specific aspects of the transport process.

SLC25A35 is a member of the SLC25A family, which is characterized by its use of the SLC25A transmembrane domain. This domain is responsible for the protein's ability to transport various molecules across cell membranes. SLC25A35 has four unique transmembrane domains, which are shown in the figure below:

The SLC25A35 transmembrane domain is made up of a伪尾尾 structure. The 伪 domain is a large extracellular domain that is involved in the protein's stability and functions as a receptor. The 尾 domain is a smaller intracellular domain that is responsible for the protein's catalytic mechanism. 纬 domain is a unique structure that is found only in SLC25A35 and is involved in the protein's stability.

SLC25A35's catalytic mechanism is based on its use of an ion-exchange mechanism. This mechanism involves the protein using two ATPase active centers on both sides to catalyze the hydrolysis of ATP. The phosphate group in the center of the ATPase active center can combine with water molecules, thereby moving the ATP molecules away from the high-energy phosphate bonds of A, leading to ATP hydrolysis. This mechanism enables SLC25A35 to efficiently transport various ions and molecules across cell membranes.

SLC25A35 has been identified as a potential drug target or biomarker due to its unique catalytic mechanism and its expression in various tissues and cells throughout the body. Studies have shown that SLC25A35 is involved in various physiological processes, including ion homeostasis, cell signaling, and neurotransmission.

One of the main reasons why SLC25A35 is considered a potential drug target is its involvement in cancer progression. Several studies have shown that SLC25A35 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, SLC25A35 has been shown to promote the growth and survival of cancer cells.

Another potential drug target for SLC25A35 is its role in neurotransmission. SLC25A35 has been shown to be involved in the transmission of various neurotransmitters across cell membranes, including dopamine, serotonin, and nitric oxide. Additionally, SLC25A35 has been shown to modulate the activity of several neurotransmitter receptors, including dopamine D2R and serotonin 5HT2A.

SLC25A35 has also been identified as a potential biomarker for several diseases, including cardiovascular disease, neurodegenerative diseases, and metabolic disorders. Several studies have shown that SLC25A35 is involved in the regulation of various physiological processes, including blood pressure, cholesterol levels, and glucose metabolism..

In conclusion, SLC25A35 is a unique and conserved transmembrane protein that is involved in the transport of various molecules across cell membranes. Its catalytic mechanism, which is based on its use of an ion-exchange mechanism, makes it a potential drug target or biomarker. SLC25A35 has been identified as a potential target for cancer, neurotransmission, and cardiovascular

Protein Name: Solute Carrier Family 25 Member 35

The "SLC25A35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets